Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
The Study has enrolled nearly 50% of its intended study sample, with initial efficacy being encouraging.
- The Study has enrolled nearly 50% of its intended study sample, with initial efficacy being encouraging.
- The clinical data generated from the Study may provide proprietary and valuable information on the safety, efficacy and dosing of oral psilocybin to support a potential pivotal clinical study and commercial initiatives in countries, such as Australia, where psilocybin can be available to licensed psychiatrists to prescribe for certain conditions.
- Methamphetamine use disorder is a chronic relapsing condition associated with substantial mental, physical, and social harms and increasing rates of mortality.
- At present, there are no approved medications to treat methamphetamine use disorder.